Germline BRCA-mutated metastatic breast cancer with positive hormone receptor

被引：0
|
作者：
Michela Palleschi
Maria Laura Iaia
Chiara Casadei
机构：
[1] Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS,
来源：
Breast Cancer Research and Treatment | 2021年 / 186卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：265 / 266
页数：1
相关论文
共 50 条
  • [21] Patient-centered outcomes in the POLO study of active maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer
    Kindler, Hedy L.
    Yoo, Hyun Kyoo
    Hettle, Robert
    Cui, Karen Y. Y.
    Joo, Seongjung
    Locker, Gershon Y.
    Golan, Talia
    CANCER, 2023, 129 (09) : 1411 - 1418
  • [22] Immune profiling of BRCA-mutated breast cancers
    Force, Jeremy Meyer
    Abbott, Sarah
    Broadwater, Gloria
    Stashko, Ilona
    Westbrook, Kelly E.
    Kimmick, Gretchen Genevieve
    Sammons, Sarah LeNoir
    Hyslop, Terry
    Brauer, Heather Ann
    Mashadi-Hossein, Afshin
    Plichta, Jennifer Kay
    Hwang, Eun-Sil Shelley
    Kauff, Noah D.
    Weinhold, Kent J.
    Nair, Smita
    Castellar, Edgardo
    Marcom, Paul Kelly
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Brain metastasis in patients with hereditary BRCA-mutated invasive breast cancer
    Garber, Haven
    Raghavendra, Akshara Singareeka
    Hess, Kenneth R.
    Arun, Banu
    Ibrahim, Nuhad K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
    Domchek, Susan M.
    Postel-Vinay, Sophie
    Im, Seock-Ah
    Park, Yeon Hee
    Delord, Jean-Pierre
    Italiano, Antoine
    Alexandre, Jerome
    You, Benoit
    Bastian, Sara
    Krebs, Matthew G.
    Wang, Ding
    Waqar, Saiama N.
    Lanasa, Mark
    Rhee, Joon
    Gao, Haiyan
    Rocher-Ros, Vidalba
    Jones, Emma, V
    Gulati, Sakshi
    Coenen-Stass, Anna
    Kozarewa, Iwanka
    Lai, Zhongwu
    Angell, Helen K.
    Opincar, Laura
    Herbolsheimer, Pia
    Kaufman, Bella
    LANCET ONCOLOGY, 2020, 21 (09): : 1155 - 1164
  • [25] Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
    Golan, Talia
    Hammel, Pascal
    Reni, Michele
    Van Cutsem, Eric
    Macarulla, Teresa
    Hall, Michael J.
    Park, Joon Oh
    Hochhauser, Daniel
    Arnold, Dirk
    Oh, Do-Youn
    Reinacher-Schick, Anke C.
    Tortora, Giampaolo
    Algul, Hana
    O'Reilly, Eileen Mary
    McGuinness, David
    Cui Karen
    Schlienger, Katia
    Locker, Gershon Y.
    Kindler, Hedy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [26] Olaparib for BRCA-mutated advanced ovarian cancer
    de Lartigue, Jane
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (06): : 206 - 208
  • [27] PARP inhibition in BRCA-mutated breast and ovarian cancers
    Chan, Stephen L.
    Mok, Tony
    LANCET, 2010, 376 (9737): : 211 - 213
  • [28] Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial
    Senkus, Elzbieta
    Delaloge, Suzette
    Domchek, Susan M.
    Conte, Pierfranco
    Im, Seock-Ah
    Xu, Binghe
    Armstrong, Anne
    Masuda, Norikazu
    Fielding, Anitra
    Robson, Mark
    Tung, Nadine
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (04) : 803 - 814
  • [29] Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
    Domchek, S.
    Postel-Vinay, S.
    Im, S-A.
    Park, Y. H.
    Delord, J-P.
    Italiano, A.
    Alexandre, J.
    You, B.
    Bastian, S.
    Krebs, M. G.
    Wang, D.
    Waqar, S.
    Lanasa, M.
    Angell, H. K.
    Lai, Z.
    Gresty, C.
    Opincar, L. M.
    Herbolsheimer, P.
    Kaufman, B.
    ANNALS OF ONCOLOGY, 2019, 30 : 477 - 477
  • [30] Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study
    Haruru Kotani
    Norikazu Masuda
    Toshinari Yamashita
    Yoichi Naito
    Tetsuhiko Taira
    Kenichi Inoue
    Masato Takahashi
    Kan Yonemori
    Shigeyuki Toyoizumi
    Yuko Mori
    Takashi Nagasawa
    Natsuki Hori
    Hiroji Iwata
    Breast Cancer, 2022, 29 : 1088 - 1098
12345